drugset / Trial / NCT01997411
Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes
Phase 2/3
Completed
48 enrolled
Eli Lilly and Company
Jaeb Center for Health Research · collabLocemia Solutions ULC · collab
RandomizedCrossoverQuadruple-blindTreatment
Summary
The purpose of this study was to assess how glucagon administered nasally, using a nasal dosing delivery device, works in children and adolescents compared with commercially-available glucagon given by injection. In addition, the safety and tolerability of glucagon given nasally was evaluated.
Timeline
- Start
- 2013-11
- Primary completion
- 2015-01
- Completion
- 2015-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Glucagon | Peptide | 0.5 mg | Intranasal |
| Subject | Glucagon | Peptide | 1 mg | Intranasal |
| Subject | Glucagon | Peptide | 2 mg | Intranasal |
| Subject | Glucagon | Peptide | 3 mg | Intranasal |